Vanguard Fiduciary Trust
LCTX icon

Vanguard Fiduciary Trust’s Lineage Cell Therapeutics LCTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
1,668,629
+344,471
+26% +$476K ﹤0.01% 2618
2026
Q1 		$2.09M Buy
+1,324,158
New +$2.23M ﹤0.01% 2542

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust's LCTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Lineage Cell Therapeutics (LCTX) stake by 26% in Q2 2026, buying an estimated $476K and bringing the position to 1,668,629 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Vanguard Fiduciary Trust first reported a position in LCTX in Q1 2026 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 1,668,629 shares of Lineage Cell Therapeutics worth $2.19M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 344,471 Lineage Cell Therapeutics shares in Q2 2026, an estimated $476K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2618 holding.
  • Vanguard Fiduciary Trust first reported a position in Lineage Cell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.